Gemtuzumab ozogamicin can reduce minimal residual disease in patients with childhood acute myeloid leukemia. - O'Hear C; Inaba H; Pounds S; Shi L; Dahl G; Bowman WP; Taub JW; Pui CH; Ribeiro RC; Coustan-Smith E; Campana D; Rubnitz JE (Cancer, 2013)